Oncology was Medpace Holdings’s largest product and service line in fiscal 2025, bringing in $747.59M of $2.53B (30%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | $467.80M | $587.10M | $651.24M | $747.59M | ||||||
| Direct Service Revenue | — | — | — | — | ||||||
| Metabolic | $296.91M | $404.84M | $431.38M | $408.55M | ||||||
| Other | $244.68M | $376.84M | $457.54M | $744.96M | ||||||
| Central Nervous System | $118.03M | $193.69M | $230.45M | $239.37M | ||||||
| Avai | $157.94M | $160.06M | $181.98M | $254.84M | ||||||
| Cardiology | $174.63M | $163.31M | $156.46M | $134.94M | ||||||
| Reimbursed Out Of Pocket Revenue | — | — | — | — | ||||||
| Revenue Net | — | — | — | — | ||||||
| Total | $1.46B | $1.89B | $2.11B | $2.53B |
Medpace Holdings brought in $2.53B from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 20.0% from $2.11B in fiscal 2024. Oncology was the largest at $747.59M (29.5%), ahead of Other at $744.96M (29.4%) and Metabolic at $408.55M (16.1%). The other three lines brought in $629.14M combined.
Compared with fiscal 2024, Other grew fastest, up 62.8% to $744.96M, while Cardiology fell the most, down 13.8% to $134.94M. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.46B to $2.53B, a compound annual growth rate of 20.1%. Oncology's share of the total fell from 32.0% to 29.5%.
Medpace Holdings (MEDP) reports its revenue by product and service. In fiscal 2025, Oncology was its largest product and service line, bringing in $747.59M (29.5% of the total), followed by Other at $744.96M (29.4%).
Oncology was Medpace Holdings' largest product and service line in fiscal 2025, bringing in $747.59M, or 29.5% of the $2.53B total across its six product and service lines.
Among Medpace Holdings' product and service lines that make up at least 2% of revenue, Other grew fastest in fiscal 2025, up 62.8% from $457.54M to $744.96M.
Every figure comes from Medpace Holdings' annual financial filings, as reported. Each line keeps the name Medpace Holdings gives it, and years follow its fiscal calendar.
Medpace Holdings' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.